Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial

Inclusion Criteria:

1. Age≥18 years and less than 75 years
2. Essential hypertension patients
3. Sedentary systolic blood pressure≥140mmHg and less than 180mmHg, and/or sedentary diastolic blood pressure≥90mmHg and less than 110mmHg
4. Reproductive women agree to take a reliable contraception measure during the trial
5. Written informed consent

Exclusion Criteria:

1. Pregnant women
2. Women within lactateion period
3. Hypersensitive to Angiotensin-Converting Enzyme Inhibitor (ACEI) or folic acid
4. Easily hypersensitiveness
5. Diagnosed secondum hypertension or skeptical secondum hypertension
6. Severe hypertension (sedentary systolic blood pressure greater than or equal to 180 mmHg and/or sedentary diastoleic blood pressure greater than or equal to 110 mmHg)
7. Severe diseases:

• Cardiovascular system
• Diagnosed cardia insufficiency (New York Health Association [NYHA] III level and higher)
• Hypertrophic obstructive cardiomyopathy (HOCM)
• Clinical significantly Valvular Disease of the Heart (VDH)
• Acute coronary syndrome or coronary artery interventional therapy or coronary artery bypass graft within three months
• Severe arrhythmia such as atrial flutter, atrial fibrillation, ventricular arrhythmia above Lown ?, atrioventricular block above II level, etc.
• Alimentary system disorders
• Active virus hepatitis
• Any of alanine aminotransferase (ALT), aspartate aminotransferase (AST), galactosylhydroxylysyl glucosyltransferase (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL), Direct Bilirubin (DB) was above 2 times of it's normal value upper limit, albumin (ALB) greater than 30 g/L
• Stomach bulk resect and gastrojejunostomy, stomach intestine malabsorption